2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
47
Polycystic Ovary Syndrome
6
Infertility
2
Hyperandrogenism
2
Stage I Prostate Adenocarcinoma AJCC v7
1
Sexual Dysfunction, Physiological
1
Prostatic Intraepithelial Neoplasia
1
Prostate Adenocarcinoma
1
Primary Dysautonomias
1
Overweight
1
Ovarian Neoplasms
1
Oligomenorrhea
1
Neoplasm Metastasis
1
Metabolic Syndrome
1
Kidney Diseases
1
Insulin Resistance
1
Hypertension
1
Hirsutism
1
Castration-resistant Prostate Cancer
1
Carcinoma, Ovarian Epithelial
1
Anovulation
1
Amenorrhea
1
Adenocarcinoma
1
Interventions
Sunitinib
4
avelumab
2
Nutrition Assessment
2
Blood Specimen Collection
2
Axitinib
2
trifluridine tipiracil drug combination
1
trebananib
1
spartalizumab
1
pembrolizumab
1
palbociclib
1
etelcalcetide hydrochloride
1
enzalutamide
1
cabozantinib
1
bicalutamide
1
atezolizumab
1
aldesleukin
1
Valsartan
1
VMBP protocol
1
Stents
1
Specimen Handling
1
Sorafenib
1
Sodium Bicarbonate
1
Resistance Training
1
Receptors, Androgen
1
Plasma Exchange
1
Pharmaceutical Preparations
1
Paclitaxel
1
Oxaliplatin
1
Nivolumab
1
Nephrotomy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Diseases
×
Flutamide
×
Clear all
NCT05700903
2026-03-02
ARCH
University of Colorado, Denver
Phase 4
Completed
10 enrolled